

Date of preparation: 2020-10-29

Issuers short name: MABION S.A.

Title of the report:

Updated information concerning the Company's cooperation with Vaxine Pty Ltd. in scope of a potential Covid-19 vaccine.

Legal basis: Article 17(1) of MAR - confidential information.

Content of the report:

In reference to current report no. 34/2020 dated 14 September 2020 on Mabion S.A. ("Company") establishing the Memorandum of Understanding ("MoU") with Vaxine Pty Ltd. ("Vaxine") concerning cooperation in scope of the product Covax-19™, the potential Covid-19 vaccine, the Company's Management Board informs that the parties have entered an agreement on the date of 29 October 2020, which regulates release of biological materials by Vaxine to the Company for explorative research of the SARS-CoV-2 vaccine antigen by the Company's laboratories.

Simultaneously, as of today, the parties to the memorandum have extended the expiration date of the MoU until 30 November 2020 in order to finalise the agreements concerning commercial development of the process, production, and commercialisation of product Covax-19™.

The companies are currently focusing on ensuring that the project is funded by the governmental institutions of individual countries or by the European Union.